Compare YTRA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YTRA | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | India | United States |
| Employees | N/A | 28 |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 60.8M |
| IPO Year | 2011 | 2024 |
| Metric | YTRA | BOLD |
|---|---|---|
| Price | $0.86 | $2.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $4.00 |
| AVG Volume (30 Days) | 16.2K | ★ 187.6K |
| Earning Date | 05-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.96 |
| 52 Week High | $2.00 | $2.79 |
| Indicator | YTRA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 78.84 |
| Support Level | $0.84 | $2.39 |
| Resistance Level | $0.97 | N/A |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.78 | 84.69 |
Yatra Online Inc is an Indian consumer travel platform provider and online travel agent. The company is organized into the following business segments; Air Ticketing which derives maximum revenue, Hotels and Packages, and Other Services. It mainly provides travel-related services, which include domestic and international air ticketing, hotel bookings, homestays, holiday packages, bus ticketing, rail ticketing, activities and ancillary services. It also involves hosting advertisements on its internet websites, the sale of rail and bus tickets, and facilitating website access to travel insurance companies. Some of its applications include Yatra Mini, Yatra Web Check-In, Yatra Corporate, and Travelguru HomeStay.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.